Compare ABEO & BRW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABEO | BRW |
|---|---|---|
| Founded | 1974 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 281.0M | 295.1M |
| IPO Year | 1980 | N/A |
| Metric | ABEO | BRW |
|---|---|---|
| Price | $5.09 | $6.88 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $18.20 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 222.1K |
| Earning Date | 03-19-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 15.59% |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $400,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,589.77 | N/A |
| P/E Ratio | $4.03 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.93 | $7.15 |
| 52 Week High | $7.54 | $8.30 |
| Indicator | ABEO | BRW |
|---|---|---|
| Relative Strength Index (RSI) | 46.51 | 34.09 |
| Support Level | $5.00 | $6.83 |
| Resistance Level | $5.41 | $6.94 |
| Average True Range (ATR) | 0.24 | 0.07 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 14.33 | 11.11 |
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
Saba Capital Income & Opportunities Fund is a diversified, closed-end management investment company. It seeks to provide investors with a high level of current income, with a secondary goal of capital appreciation. It invests globally in debt and equity securities of public and private companies, which includes, investing in closed-end funds, public and private debt instruments, and other securities.